QSAM — Qsam Biosciences Income Statement
0.000.00%
- $35.56m
- $34.18m
Annual income statement for Qsam Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.072 | 5.33 | 11.6 | 5.41 | 3.94 |
Operating Profit | -0.072 | -5.33 | -11.6 | -5.41 | -3.94 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.634 | -5.82 | -12 | -5.48 | -4.39 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.634 | -5.82 | -12 | -5.48 | -4.39 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -0.682 | -4.86 | -12 | -5.48 | -4.39 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.718 | -4.9 | -13.6 | -6.07 | -5.16 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -33.2 | -13.4 | -16.4 | -3.48 | -1.69 |